Skip to main content
    S

    Structure Therapeutics Inc. American Depositary Shares (GPCR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.57
    -1.43 (-7.15%)

    Market Cap: $1.43B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Structure Therapeutics Inc. American Depositary Shares (GPCR) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Structure Therapeutics Inc. American Depositary Shares reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$141.20M, operating cash flow was -$222.20M and free cash flow was -$225.81M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$144.76M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $287.57M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Cost of revenue$3.90M$2.60M$949.17K$623.26K$266.35K$20.03K
    Gross profit-$3.90M-$2.60M-$949.17K-$623.26K-$266.35K-$20.03K
    Research and development$225.25M$108.81M$70.10M$36.19M$29.11M$12.36K
    Operating income-$287.57M-$158.23M-$102.78M-$52.56M-$37.70M-$15.91K
    Net income-$141.20M-$122.53M-$89.62M-$51.32M-$40.01M-$15.88K
    EBITDA-$139.35M-$121.22M-$75.70M-$52.28M-$37.62M-$15.91K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$1.78M$0$0$0$1.33M
    Gross profitN/AN/A-$1.22MN/AN/A-$853.99K-$686.98K$890.66K-$267.18K-$231.74K-$658.93K$1.05M
    Operating income-$156.33M-$118.63M-$89.65M$23.99M-$73.79M-$70.45M-$56.31M-$47.06M-$45.84M-$33.32M-$32.02M-$30.99M
    Net income-$144.76M-$106.16M-$76.19M$33.00M-$65.71M-$61.66M-$46.83M-$36.48M-$33.98M-$26.03M-$26.04M-$24.50M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.88M by $796.75M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$1.58B$903.33M$482.02M$97.84M$111.16M$38.70M
    Current assets$1.57B$891.21M$473.61M$93.09M$109.25M$38.42M
    Cash and equivalents$799.62M$169.51M$129.79M$26.09M$105.31M$16.35M
    Total liabilities$67.54M$38.49M$29.05M$212.99M$175.89M$61.17M
    Short-term debt$2.88M$1.70M$1.44M$260.00K$349.00K$147.00K
    Shareholder equity$1.52B$864.84M$452.97M-$115.14M-$64.73M-$22.47M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.33B$1.43B$1.51B$1.58B$832.16M$816.44M$866.55M$903.33M$933.22M$947.03M$457.23M$482.02M
    Total liabilities$112.55M$71.01M$61.03M$67.54M$62.14M$44.36M$41.91M$38.49M$36.42M$26.00M$27.41M$29.05M
    Cash and equivalents$222.03M$272.64M$316.17M$799.62M$102.91M$147.02M$152.12M$169.51M$172.13M$381.63M$97.83M$129.79M
    Shareholder equity$1.22B$1.35B$1.45B$1.52B$770.02M$772.08M$824.64M$864.84M$896.80M$921.03M$429.82M$452.97M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$222.20M-$116.64M-$79.49M-$46.12M-$32.16M-$14.28M
    Capital expenditures$3.61M$1.29M$2.17M$155.00K$1.21M$19.00K
    Free cash flow-$225.81M-$117.93M-$81.66M-$46.27M-$33.37M-$14.30M
    Investing cash flow$89.80M-$358.91M-$268.34M-$62.11M$17.86M-$21.15M
    Financing cash flow$762.52M$515.26M$451.53M$29.01M$103.25M$25.84M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$101.70M-$120.11M$15.28M-$64.42M-$51.00M-$54.56M-$52.23M-$36.47M-$19.70M-$26.39M-$34.08M-$21.73M
    Capital expenditures$3.65M$42.00K$1.19M$1.50M$1.57M$232.00K$314.00K$16.00K$685.00K$427.00K$162.00K$1.16M
    Free cash flow-$105.34M-$120.16M$14.09M-$65.91M-$52.57M-$54.79M-$52.54M-$36.48M-$20.38M-$26.82M-$34.24M-$22.89M
    Last 12 quarters

    Frequently Asked Questions About GPCR

    What is Structure Therapeutics Inc. American Depositary Shares' annual revenue?

    Structure Therapeutics Inc. American Depositary Shares reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Structure Therapeutics Inc. American Depositary Shares profitable?

    No. Structure Therapeutics Inc. American Depositary Shares reported net income of -$141.20M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does GPCR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$222.20M minus capital expenditures of $3.61M produced free cash flow of -$225.81M.

    How much debt does Structure Therapeutics Inc. American Depositary Shares have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.88M and cash and equivalents of $799.62M.